GlassScriptPhysician profile
James Griffin
NPI 1902136146
$7,424.57
in general payments reported to CMS, 2019-2025
29 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 76% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.33 · 2021: $156 · 2022: $129 · 2023: $306 · 2024: $5,387 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,000 · Food and Beverage: $1,550 · Travel and Lodging: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,000.00 |
| Food and Beverage | $1,550.25 |
| Travel and Lodging | $562.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,466.88 | 2023-2025 | Da Vinci Surgical System |
| Ethicon US, LLC | $183.31 | 2021-2025 | Echelon Circular, Echelon Flex, Prolene |
| Smith+Nephew, INC. | $80.45 | 2023-2025 | Stravix, Grafix, Grafix Pl |
| Lexington Medical, INC. | $75.75 | 2023 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Kci USA, INC. | $47.39 | 2020-2023 | V.A.C.Ulta, Prevena |
| Stryker Corporation | $46.89 | 2021 | |
| Medtronic, INC. | $43.55 | 2023-2025 | Signia, Gia |
| Abbvie INC. | $43.11 | 2023 | |
| Atricure, INC. | $35.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $34.49 | 2022-2023 | Lynparza |
| Integra Lifesciences Corporation | $31.56 | 2022 | |
| Adc Therapeutics America, INC. | $30.03 | 2024 | |
| Merck Sharp & Dohme LLC | $26.03 | 2024 | Welireg, Keytruda |
| Blueprint Medicines Corporation | $21.78 | 2023 | Ayvakit |
| Seagen INC. | $21.64 | 2023 | Adcetris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $20.94 | 2025 | Apretude |
| Edwards Lifesciences Corporation | $18.51 | 2022 | |
| Exelixis INC. | $18.46 | 2024 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $18.31 | 2023 | Libtayo |
| Agios Pharmaceuticals, INC. | $17.71 | 2024 | |
| Glaxosmithkline, LLC. | $17.53 | 2023 | Ojjaara |
| Beone Medicines USA, INC. | $17.45 | 2025 | Tevimbra |
| Sobi, INC | $17.42 | 2024 | |
| Telix Pharmaceuticals | $17.08 | 2025 | Illuccix |
| Conmed Corporation | $16.81 | 2025 | Airseal |
| Emd Serono, INC. | $14.37 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.18 | 2025 | Givlaari |
| Mimedx Group, INC. | $14.18 | 2025 | |
| Spectrum Pharmaceuticals INC. | $13.25 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.